Monoclonal antibody antagonists to IL-3
AssigneeMedvet Science Pty. Ltd.
InventorAngel F Lopez
Life of this patent
Estimating the term…
Abstract
Anti IL-3 Receptor alpha chain monoclonal antibody (MoAb) is the product of a hybridoma cell line designated 7G3. The MoAb acts as an antagonist to IL-3 in vitro activity. The MoAb binds to the N terminal domain of the IL-3 receptor alpha chain and does so competitively with IL-3 which indicates that this is, at least in part, involved in IL-3 binding. Treatment with the MoAb or fragment thereof, whether recombinant or otherwise, may be suitable for the treatment of one or more of the following conditions: myeloid leukemias, lymphomas such as follicular B cell lymphoma, or the alleviation of allergies.
Claims10
A method of treating a patient suffering from a condition resulting from an overproduction of IL-3, said method comprising the step of administering to said patient a monoclonal antibody or antibody fragment thereof with a binding specificity for amino acid residues 19-49 of said IL-3 receptor α-chain in an effective amount to antagonize functions of said IL-3.
A pharmaceutical preparation comprising a monoclonal antibody or fragment thereof with a binding specificity for amino acid residues 19-49 of the IL-3 receptor α-chain in combination with a physiologically acceptable carrier, said antibody or antibody fragment being included in said preparation in an amount effective to antagonize functions of IL-3 to treat a condition resulting from overexpression of IL-3.
Dependencies are inferred from the claim text.